AU4297300A - Use of coxsackie viruses for improving cell transfection - Google Patents

Use of coxsackie viruses for improving cell transfection

Info

Publication number
AU4297300A
AU4297300A AU42973/00A AU4297300A AU4297300A AU 4297300 A AU4297300 A AU 4297300A AU 42973/00 A AU42973/00 A AU 42973/00A AU 4297300 A AU4297300 A AU 4297300A AU 4297300 A AU4297300 A AU 4297300A
Authority
AU
Australia
Prior art keywords
cell transfection
improving cell
coxsackie viruses
coxsackie
viruses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU42973/00A
Inventor
Reinhard Kandolf
Jan-Heiner Kupper
Hans-Christoph Selinka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaetsklinikum Tuebingen
Original Assignee
Eberhard Karls Universitaet Tuebingen
Universitaetsklinikum Tuebingen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eberhard Karls Universitaet Tuebingen, Universitaetsklinikum Tuebingen filed Critical Eberhard Karls Universitaet Tuebingen
Publication of AU4297300A publication Critical patent/AU4297300A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32341—Use of virus, viral particle or viral elements as a vector
    • C12N2770/32343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU42973/00A 1999-04-23 2000-04-20 Use of coxsackie viruses for improving cell transfection Abandoned AU4297300A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19918446A DE19918446A1 (en) 1999-04-23 1999-04-23 Use of Coxsackievirus B3 to improve the transfection of cells
DE19918446 1999-04-23
PCT/EP2000/003588 WO2000065075A1 (en) 1999-04-23 2000-04-20 Use of coxsackie viruses for improving cell transfection

Publications (1)

Publication Number Publication Date
AU4297300A true AU4297300A (en) 2000-11-10

Family

ID=7905606

Family Applications (1)

Application Number Title Priority Date Filing Date
AU42973/00A Abandoned AU4297300A (en) 1999-04-23 2000-04-20 Use of coxsackie viruses for improving cell transfection

Country Status (4)

Country Link
EP (1) EP1173595A1 (en)
AU (1) AU4297300A (en)
DE (1) DE19918446A1 (en)
WO (1) WO2000065075A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3759412B2 (en) 1999-05-19 2006-03-22 エベルハルト‐カルルス‐ウニベアジテート、テュービンゲン、ウニベアジテートスクリニクム Use of antibodies for the detection and / or quantification and / or isolation of basophils and / or mast cells and / or their precursor cells and / or their surface structures
GB2459436A (en) * 2008-04-08 2009-10-28 Henderson Morley Plc Vaccine adjuvant
CN107760719B (en) * 2017-10-24 2020-09-22 北京领柯生物科技有限公司 Application of Coxsackie virus in adoptive immune gene delivery system
CN114107392A (en) * 2021-11-22 2022-03-01 昆明理工大学 Preparation method of CVB5 virus-like particles

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US6071742A (en) * 1997-03-05 2000-06-06 Board Of Regents Of The University Of Nebraska Coxsackie virus as a vector for delivery of anti-inflammatory cytokines

Also Published As

Publication number Publication date
DE19918446A1 (en) 2000-11-23
EP1173595A1 (en) 2002-01-23
WO2000065075A1 (en) 2000-11-02

Similar Documents

Publication Publication Date Title
AU3867400A (en) Methods of using bioelastomers
AU1803601A (en) Methods and compositions for the introduction of molecules into cells
AU5731400A (en) Methods of preparing electrochemical cells
AU1796601A (en) Methods of preparing electrochemical cells
AU3247100A (en) Slotted hammermill hammer
AU3706700A (en) Positively charged membrane
AU6422400A (en) Disposable urinary aid
AU6111000A (en) Inhibitors of viral helcase
AU5003600A (en) Charged membrane
AU6078500A (en) Combination therapy for conditions leading to bone loss
AU2001233132A1 (en) Hybrid adeno-retroviral vector for the transfection of cells
AUPP938799A0 (en) Electrodes
AUPR074500A0 (en) Treatment of t cell disorders
AU1796501A (en) Methods of preparing electrochemical cells
AU3420700A (en) Arrangement of electrochemical cells
AU1548401A (en) Use of disease-associated gene
AU4297300A (en) Use of coxsackie viruses for improving cell transfection
AU2379800A (en) Antisense modulation of fadd expression
AUPQ314799A0 (en) Bone cell factor
AU1661501A (en) Holder for graphite electrodes
AU2002316419A1 (en) Improvement of viral uptake into cells and tissues
AU4774200A (en) Long term cell culture of human carcinoma
AU6533700A (en) Methods of gene expression monitoring
AU6382000A (en) Genome analysis
AU4459100A (en) Cell cycle genes and methods of use

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase